Maury Raycroft
Stock Analyst at Jefferies
(0.38)
# 3,550
Out of 4,667 analysts
51
Total ratings
15.38%
Success rate
-31.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Initiates: Buy | $6 | $2.64 | +127.27% | 1 | Nov 18, 2024 | |
| INZY Inozyme Pharma | Assumes: Buy | $16 → $17 | $2.79 | +509.32% | 1 | Aug 13, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $4.08 | +365.69% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $2.99 | +401.67% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $20.77 | +87.77% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $1.09 | +450.46% | 1 | Mar 13, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Upgrades: Buy | $4 → $46 | $16.08 | +186.07% | 1 | Mar 6, 2024 | |
| MGX Metagenomi | Initiates: Buy | $23 | $1.65 | +1,293.94% | 1 | Mar 5, 2024 | |
| TPST Tempest Therapeutics | Initiates: Buy | $15 | $0.90 | +1,569.63% | 1 | Feb 8, 2024 | |
| BCRX BioCryst Pharmaceuticals | Upgrades: Buy | $11 | $7.30 | +50.68% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $6 → $9 | $0.94 | +858.26% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.37 | +483.94% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $45.75 | -86.89% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $18.71 | +300.86% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $248.79 | -6.75% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.01 | +119.56% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $15.87 | +70.13% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.71 | +192.40% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $12.78 | +275.59% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $4.67 | +670.88% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $4.96 | +2,016.94% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $47.26 | +263.94% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $0.88 | +2,286.36% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.43 | +1,834.16% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 → $40 | $2.72 | +1,370.59% | 5 | Aug 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $7.49 | +2,970.76% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $13.12 | +220.12% | 3 | Nov 1, 2017 |
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $2.64
Upside: +127.27%
Inozyme Pharma
Aug 13, 2024
Assumes: Buy
Price Target: $16 → $17
Current: $2.79
Upside: +509.32%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $4.08
Upside: +365.69%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $2.99
Upside: +401.67%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $20.77
Upside: +87.77%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.09
Upside: +450.46%
Corbus Pharmaceuticals Holdings
Mar 6, 2024
Upgrades: Buy
Price Target: $4 → $46
Current: $16.08
Upside: +186.07%
Metagenomi
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.65
Upside: +1,293.94%
Tempest Therapeutics
Feb 8, 2024
Initiates: Buy
Price Target: $15
Current: $0.90
Upside: +1,569.63%
BioCryst Pharmaceuticals
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.30
Upside: +50.68%
May 12, 2023
Upgrades: Buy
Price Target: $6 → $9
Current: $0.94
Upside: +858.26%
Jan 31, 2023
Initiates: Buy
Price Target: $8
Current: $1.37
Upside: +483.94%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $45.75
Upside: -86.89%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $18.71
Upside: +300.86%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $248.79
Upside: -6.75%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $5.01
Upside: +119.56%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $15.87
Upside: +70.13%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.71
Upside: +192.40%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $12.78
Upside: +275.59%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $4.67
Upside: +670.88%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $4.96
Upside: +2,016.94%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $47.26
Upside: +263.94%
Mar 31, 2021
Initiates: Buy
Price Target: $21
Current: $0.88
Upside: +2,286.36%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.43
Upside: +1,834.16%
Aug 28, 2018
Upgrades: Buy
Price Target: $18 → $40
Current: $2.72
Upside: +1,370.59%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $7.49
Upside: +2,970.76%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $13.12
Upside: +220.12%